Sherene Loi, MD, PhD
Advertisement
Articles by Sherene Loi, MD, PhD
21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial
ByGabriel N. Hortobagyi, MD, FACP,Daniil Stroyakovskiy,Denise A. Yardley, MD,Chiun-Sheng Huang,Peter A. Fasching,John Crown,Aditya Bardia, MD, MPH, FASCO,Stephen Chia,Seock-Ah Im,Miguel Martin, MD, PhD,Sherene Loi, MD, PhD,Binghe Xu,Sara A. Hurvitz, MD,Carlos Barrios,Michael Untch, MD, PhD,Rebecca Moroose,Frances Visco,Federico Parnizari,Farhat Ghaznawi,Zheng Li,Sorcha Waters,Arunava Chakravartty,Dennis J. Slamon, MD, PhD
In this interview we discuss some of the novel therapeutics in development for HER2-amplified breast cancer.
The future role of immunotherapy in breast cancer is currently being actively investigated, so we anticipate that we will soon have further clues about the role of immunotherapy in breast cancer patients.
Advertisement
Latest Updated Articles
22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEEPublished: June 24th 2025 | Updated:
- Immune Targeting in Breast Cancer: In Whom and With What?
Published: May 15th 2015 | Updated:
Novel Therapies in Development for HER2-Amplified Breast CancerPublished: June 27th 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer
2
Nivolumab/Ipilimumab Improves Real-World Melanoma Outcomes Vs Pembrolizumab
3
Neoadjuvant Cemiplimab/SBRT Yields Improved DFS in Resectable HCC
4
Novel Anti-CD5 Therapy Earns FDA RMAT Designation in T-Cell Lymphoma
5
